Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berdazimer sodium - SB 206 - Novan Inc

Drug Profile

Berdazimer sodium - SB 206 - Novan Inc

Alternative Names: Berdazimer gel; Berdazimer gel 10.3%; MAP3-NONOate - SB-206; NI-MC101; NVN-1000-SB-206-Novan; NVN1000-SB206; SB-206; ZELSUVMI

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Novan Inc; Sato
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antipsoriatics; Antivirals; Esters; Free radicals; Macromolecular substances; Nitrogen oxides; Nitroso compounds; Non-opioid analgesics; Propylamines; Silicates; Silicon compounds; Skin disorder therapies; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Nitric oxide donors; NLRP3 protein inhibitors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Molluscum contagiosum
  • Phase II Viral infections
  • Discontinued Genital warts; Human papillomavirus infections; Staphylococcal infections

Most Recent Events

  • 07 Mar 2024 Phase-II clinical trials in Viral infections in Japan (Topical) before March 2024 (Ligand Pharmaceuticals, Form-10K)
  • 10 Jan 2024 Discontinued - Phase-II for Genital warts in USA (Topical), before January 2024 (Novan pipeline, January 2024)
  • 10 Jan 2024 Discontinued - Preclinical for Human papillomavirus infections in USA (Topical), before January 2024 (Novan pipeline, January 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top